JP2008512484A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008512484A5 JP2008512484A5 JP2007531364A JP2007531364A JP2008512484A5 JP 2008512484 A5 JP2008512484 A5 JP 2008512484A5 JP 2007531364 A JP2007531364 A JP 2007531364A JP 2007531364 A JP2007531364 A JP 2007531364A JP 2008512484 A5 JP2008512484 A5 JP 2008512484A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- heart
- phosphatase inhibitor
- protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 38
- 239000002245 particle Substances 0.000 claims 9
- 229940122907 Phosphatase inhibitor Drugs 0.000 claims 7
- 210000004351 coronary vessel Anatomy 0.000 claims 7
- 108091006086 inhibitor proteins Proteins 0.000 claims 7
- 108020004707 nucleic acids Proteins 0.000 claims 7
- 102000039446 nucleic acids Human genes 0.000 claims 7
- 150000007523 nucleic acids Chemical class 0.000 claims 7
- 230000003612 virological effect Effects 0.000 claims 7
- 230000017531 blood circulation Effects 0.000 claims 6
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 claims 5
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 claims 5
- 102000004097 Protein phosphatase inhibitor 1 Human genes 0.000 claims 5
- 108090000506 Protein phosphatase inhibitor 1 Proteins 0.000 claims 5
- 241000700605 Viruses Species 0.000 claims 5
- 230000000694 effects Effects 0.000 claims 5
- 230000000747 cardiac effect Effects 0.000 claims 4
- 239000012634 fragment Substances 0.000 claims 4
- 241000702421 Dependoparvovirus Species 0.000 claims 3
- 206010019280 Heart failures Diseases 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 235000018102 proteins Nutrition 0.000 claims 3
- 108090000623 proteins and genes Proteins 0.000 claims 3
- 102000004169 proteins and genes Human genes 0.000 claims 3
- 210000003462 vein Anatomy 0.000 claims 3
- 241000701022 Cytomegalovirus Species 0.000 claims 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims 2
- 241000713666 Lentivirus Species 0.000 claims 2
- 102220540010 Protein phosphatase 1 regulatory subunit 1A_T35D_mutation Human genes 0.000 claims 2
- 235000001014 amino acid Nutrition 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 2
- 235000003704 aspartic acid Nutrition 0.000 claims 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims 2
- 210000004204 blood vessel Anatomy 0.000 claims 2
- 239000011575 calcium Substances 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 239000003153 chemical reaction reagent Substances 0.000 claims 2
- 230000004217 heart function Effects 0.000 claims 2
- 210000001519 tissue Anatomy 0.000 claims 2
- 108091006112 ATPases Proteins 0.000 claims 1
- 241000972680 Adeno-associated virus - 6 Species 0.000 claims 1
- 102000057290 Adenosine Triphosphatases Human genes 0.000 claims 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical group [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims 1
- 108091026890 Coding region Proteins 0.000 claims 1
- 102000005604 Myosin Heavy Chains Human genes 0.000 claims 1
- 108010084498 Myosin Heavy Chains Proteins 0.000 claims 1
- 102000016349 Myosin Light Chains Human genes 0.000 claims 1
- 108010067385 Myosin Light Chains Proteins 0.000 claims 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims 1
- 239000004473 Threonine Substances 0.000 claims 1
- 102000004987 Troponin T Human genes 0.000 claims 1
- 108090001108 Troponin T Proteins 0.000 claims 1
- 108010067390 Viral Proteins Proteins 0.000 claims 1
- 230000005856 abnormality Effects 0.000 claims 1
- 230000006793 arrhythmia Effects 0.000 claims 1
- 206010003119 arrhythmia Diseases 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 229910052791 calcium Inorganic materials 0.000 claims 1
- 230000003913 calcium metabolism Effects 0.000 claims 1
- 210000004413 cardiac myocyte Anatomy 0.000 claims 1
- 230000008602 contraction Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000006870 function Effects 0.000 claims 1
- 230000010247 heart contraction Effects 0.000 claims 1
- 208000028867 ischemia Diseases 0.000 claims 1
- 230000002530 ischemic preconditioning effect Effects 0.000 claims 1
- 230000006371 metabolic abnormality Effects 0.000 claims 1
- 230000004060 metabolic process Effects 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 210000000663 muscle cell Anatomy 0.000 claims 1
- 230000002107 myocardial effect Effects 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 210000004165 myocardium Anatomy 0.000 claims 1
- 238000004806 packaging method and process Methods 0.000 claims 1
- 102000005681 phospholamban Human genes 0.000 claims 1
- 108010059929 phospholamban Proteins 0.000 claims 1
- 230000026731 phosphorylation Effects 0.000 claims 1
- 238000006366 phosphorylation reaction Methods 0.000 claims 1
- 230000001105 regulatory effect Effects 0.000 claims 1
- 230000004043 responsiveness Effects 0.000 claims 1
- 210000001908 sarcoplasmic reticulum Anatomy 0.000 claims 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 claims 1
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 claims 1
- 241000701161 unidentified adenovirus Species 0.000 claims 1
- 230000002861 ventricular Effects 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US60821404P | 2004-09-09 | 2004-09-09 | |
| PCT/US2005/032162 WO2006029319A2 (en) | 2004-09-09 | 2005-09-08 | Modulating phosphatase activity in cardiac cells |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008512484A JP2008512484A (ja) | 2008-04-24 |
| JP2008512484A5 true JP2008512484A5 (enExample) | 2008-10-23 |
Family
ID=36037020
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007531364A Pending JP2008512484A (ja) | 2004-09-09 | 2005-09-08 | 心臓細胞におけるホスファターゼ活性の調節 |
Country Status (7)
| Country | Link |
|---|---|
| US (4) | US9114148B2 (enExample) |
| EP (1) | EP1791432A4 (enExample) |
| JP (1) | JP2008512484A (enExample) |
| CN (1) | CN101056539B (enExample) |
| AU (1) | AU2005282352B2 (enExample) |
| CA (1) | CA2579519A1 (enExample) |
| WO (1) | WO2006029319A2 (enExample) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006033679A2 (en) * | 2004-05-25 | 2006-03-30 | Chimeracore, Inc. | Self-assembling nanoparticle drug delivery system |
| EP1994043A4 (en) * | 2006-02-10 | 2009-05-20 | Univ Cincinnati | PHOSPHATASE INHIBITOR PROTEIN 1 AS A REGULATOR OF HEART FUNCTION |
| DE602007005366D1 (de) * | 2006-04-07 | 2010-04-29 | Chimeros Inc | Zusammensetzungen und verfahren zur behandlung von b-zellen-malignomen |
| JP5623740B2 (ja) * | 2006-07-25 | 2014-11-12 | セラドン・コーポレーション | 遺伝子治療用アデノ随伴ウイルスベクターの長期順行性の心外膜冠動脈注入 |
| WO2008124165A2 (en) * | 2007-04-09 | 2008-10-16 | Chimeros, Inc. | Self-assembling nanoparticle drug delivery system |
| CA2685592C (en) * | 2007-05-02 | 2018-08-07 | Intrexon Corporation | Pp1 ligands |
| ES2634118T3 (es) | 2009-02-11 | 2017-09-26 | The University Of North Carolina At Chapel Hill | Vectores de virus modificados y métodos para fabricar y utilizar los mismos |
| WO2010120874A2 (en) | 2009-04-14 | 2010-10-21 | Chimeros, Inc. | Chimeric therapeutics, compositions, and methods for using same |
| JP5370969B2 (ja) * | 2010-02-23 | 2013-12-18 | 国立大学法人金沢大学 | 心筋障害の検査方法 |
| EP4234571A3 (en) | 2011-02-10 | 2023-09-27 | The University of North Carolina at Chapel Hill | Viral vectors with modified transduction profiles and methods of making and using the same |
| AU2012305714A1 (en) | 2011-09-09 | 2014-03-27 | Biomed Realty, L.P. | Methods and compositions for controlling assembly of viral proteins |
| CA2904396A1 (en) | 2013-03-15 | 2014-09-18 | The University Of North Carolina At Chapel Hill | Methods and compositions for dual glycan binding aav vectors |
| WO2016115382A1 (en) | 2015-01-14 | 2016-07-21 | The University Of North Carolina At Chapel Hill | Methods and compositions for targeted gene transfer |
| CN113244399A (zh) | 2015-01-26 | 2021-08-13 | 耶鲁大学 | 利用酪氨酸激酶抑制剂的组合物和方法 |
| CA2977071A1 (en) | 2015-02-20 | 2016-08-25 | Board Of Regents, The University Of Texas System | Methods and compositions for attenuated chlamydia as vaccine and vector |
| EP3831842A1 (en) | 2015-09-28 | 2021-06-09 | The University of North Carolina at Chapel Hill | Methods and compositions for antibody-evading virus vectors |
| US11246905B2 (en) | 2016-08-15 | 2022-02-15 | President And Fellows Of Harvard College | Treating infections using IdsD from Proteus mirabilis |
| EP4303225B1 (en) | 2017-03-15 | 2025-11-26 | The University of North Carolina at Chapel Hill | Polyploid adeno-associated virus vectors and methods of making and using the same |
| CN112041442A (zh) | 2018-02-28 | 2020-12-04 | 北卡罗来纳大学查佩尔希尔分校 | 用于逃避抗体的病毒载体的方法和组合物 |
| WO2019195449A1 (en) | 2018-04-03 | 2019-10-10 | Stridebio, Inc. | Antibody-evading virus vectors |
| CN112543766A (zh) | 2018-04-03 | 2021-03-23 | 斯特里迪比奥公司 | 抗体逃避性病毒载体 |
| EP3773743A1 (en) | 2018-04-03 | 2021-02-17 | Stridebio, Inc. | Virus vectors for targeting ophthalmic tissues |
| CN113727992A (zh) | 2019-03-21 | 2021-11-30 | 斯特里迪比奥公司 | 重组腺相关病毒载体 |
| CN110367188A (zh) * | 2019-04-04 | 2019-10-25 | 上海大学 | 心肌层转染慢病毒的小鼠模型的构建方法 |
| WO2020219656A1 (en) | 2019-04-26 | 2020-10-29 | The University Of North Carolina At Chapel Hill | Methods and compositions for dual glycan binding aav2.5 vector |
| TW202128736A (zh) | 2019-10-17 | 2021-08-01 | 美商史崔德生物公司 | 用於治療ｃ型尼曼—匹克病之腺相關病毒載體 |
| MY209860A (en) | 2020-02-13 | 2025-08-07 | Tenaya Therapeutics Inc | Gene therapy vectors for treating heart disease |
| EP4192580A4 (en) * | 2020-08-05 | 2025-06-18 | AskBio Inc. | Methods for treating heart disease and congestive heart failure and administration of AAV vectors |
| TW202227632A (zh) | 2020-08-19 | 2022-07-16 | 美商史崔德生物公司 | 用於治療雷特症候群之腺相關病毒載體 |
| WO2022093769A1 (en) | 2020-10-28 | 2022-05-05 | The University Of North Carolina At Chapel Hill | Methods and compositions for dual glycan binding aav2.5 vector |
| JP2023547992A (ja) | 2020-10-28 | 2023-11-15 | ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル | 二重グリカン結合ａａｖ２．５ベクターのための方法および組成物 |
| TW202242124A (zh) | 2021-01-14 | 2022-11-01 | 美商史崔德生物公司 | 靶向ｔ細胞之ａａｖ載體 |
| WO2022221529A1 (en) | 2021-04-16 | 2022-10-20 | Asklepios Biopharmaceutical, Inc. | Rational polyploid aav virions that cross the blood brain barrier and elicit reduced humoral response |
| WO2023150687A1 (en) | 2022-02-04 | 2023-08-10 | Ginkgo Bioworks, Inc. | Recombinant adeno-associated virus vectors, and methods of use thereof |
| WO2024124019A2 (en) | 2022-12-07 | 2024-06-13 | Ginkgo Bioworks, Inc. | Aav vectors targeting hematopoietic stem cells |
| KR20240173703A (ko) * | 2023-06-05 | 2024-12-13 | (주)벳바젠 | 포스포람반의 단백질 포스파타아제 1-매개 탈인산화 억제용 데코이 펩타이드를 암호화하는 뉴클레오타이드 및 ccn5 단백질 또는 이의 단편을 암호화하는 뉴클레오타이드를 포함하는 유전자 컨스트럭트 및 이의 용도 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5589375A (en) * | 1992-10-06 | 1996-12-31 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E. V. | PTP 1D: a novel protein tyrosine phosphatase |
| US7745416B2 (en) * | 1995-04-11 | 2010-06-29 | The Regents Of The University Of California | Method for in vivo regulation of cardiac muscle contractility |
| US20050095227A1 (en) * | 1997-07-22 | 2005-05-05 | The General Hospital Corporation | Treating heart failure |
| US20020040010A1 (en) * | 1997-07-22 | 2002-04-04 | Anthony Rosenzweig | Use of agents to treat heart disorders |
| WO2000022152A1 (en) * | 1998-10-13 | 2000-04-20 | Avigen, Inc. | Compositions and methods for producing recombinant adeno-associated virus |
| WO2002055710A2 (en) * | 2001-01-11 | 2002-07-18 | Bayer Ag | Regulation of human purple acid phosphatase |
| AU2002249947A1 (en) * | 2001-01-15 | 2002-07-30 | Henry Ford Health System | Inhibition of protein-phosphatases for the treatment of heart failure |
| US20020159978A1 (en) * | 2001-02-06 | 2002-10-31 | James Allen | Muscle-directed gene transfer by use of recombinant AAV-1 and AAV-6 virions |
| US7655467B2 (en) * | 2003-11-14 | 2010-02-02 | The University Of Washington | Compositions and methods for systemic nucleic acid sequence delivery |
| EP1994043A4 (en) | 2006-02-10 | 2009-05-20 | Univ Cincinnati | PHOSPHATASE INHIBITOR PROTEIN 1 AS A REGULATOR OF HEART FUNCTION |
-
2005
- 2005-09-08 WO PCT/US2005/032162 patent/WO2006029319A2/en not_active Ceased
- 2005-09-08 CN CN2005800383370A patent/CN101056539B/zh not_active Expired - Fee Related
- 2005-09-08 CA CA002579519A patent/CA2579519A1/en not_active Abandoned
- 2005-09-08 US US11/662,439 patent/US9114148B2/en active Active
- 2005-09-08 AU AU2005282352A patent/AU2005282352B2/en not_active Ceased
- 2005-09-08 JP JP2007531364A patent/JP2008512484A/ja active Pending
- 2005-09-08 EP EP05804009A patent/EP1791432A4/en not_active Withdrawn
-
2016
- 2016-03-09 US US15/065,507 patent/US11213534B2/en not_active Expired - Lifetime
-
2019
- 2019-04-11 US US16/381,781 patent/US12343353B2/en not_active Expired - Lifetime
- 2019-12-31 US US16/731,585 patent/US20200171059A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008512484A5 (enExample) | ||
| Müller et al. | Targeting the heart with gene therapy-optimized gene delivery methods | |
| JP2020518268A5 (enExample) | ||
| JP2007531564A (ja) | 遺伝子発現を制御する埋め込み可能なシステム | |
| JP2009525757A5 (enExample) | ||
| Ly et al. | Gene therapy in the treatment of heart failure | |
| Bull et al. | Effect of Terplex/VEGF-165 gene therapy on left ventricular function and structure following myocardial infarction: VEGF gene therapy for myocardial infarction | |
| EP1317289B1 (en) | Dominant negative PLB mutant for use in treating cardiac disease | |
| US20030072744A1 (en) | Methods of altering cardiac cell phenotype | |
| HK1222884A1 (zh) | 用於治疗心力衰竭和增加心脏功能的不能产生环腺苷酸的腺苷酸环化酶和组合物和方法 | |
| Xu et al. | Optimizing drug delivery for enhancing therapeutic efficacy of recombinant human endostatin in cancer treatment | |
| EP3125948A2 (en) | Systemic delivery of virus vectors encoding urocortin-2 and related genes to treat diabetes-related cardiac dysfunction and congestive heart failure | |
| AU2020411330A1 (en) | Liver-specific promoter and application thereof | |
| KR20230084542A (ko) | 플라코필린 2 유전자 치료 방법 및 조성물 | |
| JP2003513942A (ja) | インビボ遺伝子送達による心血管疾患を処理するための技術および組成物 | |
| CN100350979C (zh) | 核酸和血管活性剂相组合用于加强的基因投递 | |
| EP1581241A2 (en) | Stimulation of vascularization with vegf-b | |
| Avril et al. | Defining the success of cardiac gene therapy: how can nuclear imaging contribute? | |
| CN101495627A (zh) | 用于基因疗法的延长的腺相关病毒载体的顺行性心外膜冠状动脉输注 | |
| Askari et al. | Targeted gene therapy for the treatment of cardiac dysfunction | |
| WO2018090042A1 (en) | Methods of treating heart failure | |
| Fargnoli et al. | Gene therapy in heart failure | |
| CN115885043A (zh) | 用于dwarf开放阅读框的腺相关病毒载体 | |
| Schroder et al. | Transcriptional targeting approaches in cardiac gene transfer using AAV vectors. Pathogens 2023; 12: 1301 | |
| JP2006514929A (ja) | 冠動脈疾患の治療 |